Subcutaneous Immunoglobulin (SCIG) Market : Technology Advancements, Industry Insights, Trends And Forecast 2033

Subcutaneous immunoglobulin (SCIG) refers to a method of administering immunoglobulin therapy in which the medication is delivered under the skin, rather than into a vein. This method allows for slower absorption of the medication, reducing the risk of side effects compared to intravenous administration. SCIG is used to treat various immune deficiencies, providing a convenient and effective way to boost the immune system.

Aug 27, 2024 - 18:26

Subcutaneous Immunoglobulin (SCIG) Market : Technology Advancements, Industry Insights, Trends And Forecast 2033

Subcutaneous immunoglobulin (SCIG) refers to a method of administering immunoglobulin therapy in which the medication is delivered under the skin, rather than into a vein. This method allows for slower absorption of the medication, reducing the risk of side effects compared to intravenous administration. SCIG is used to treat various immune deficiencies, providing a convenient and effective way to boost the immune system.

Sizing and Forecast
The subcutaneous immunoglobulin market size has grown rapidly in recent years. It will grow from $11.19 billion in 2023 to $12.72 billion in 2024 at a compound annual growth rate (CAGR) of 13.7%. The growth in the historic period can be attributed to the increased prevalence of immunodeficiency disorders, rise in the patient preference for home-based care, enhanced therapeutic efficacy, growth in the awareness and diagnosis rates, growth in the favorable reimbursement policies.

The subcutaneous immunoglobulin market size is expected to see rapid growth in the next few years. It will grow to $21.38 billion in 2028 at a compound annual growth rate (CAGR) of 13.9%. The growth in the forecast period can be attributed to the growing prevalence of neurological disorders, increasing prevalence of autoimmune diseases, rising awareness and acceptance of immunoglobulin therapy, expanding applications in neurology and dermatology, expansion of healthcare facilities. Major trends in the forecast period include advancements in drug delivery systems, increasing demand for home infusion therapies, developments in antibody therapy, Innovations in formulations, and Innovations in SCIG.

Order your report now for swift delivery, visit the link:
https://www.thebusinessresearchcompany.com/report/subcutaneous-immunoglobulin-scig-global-market-report

Segmentation & Regional Insights
The subcutaneous immunoglobulin (SCIG) market covered in this report is segmented –

1) By Product Type: Immunoglobulin A (IgA), Immunoglobulin G (IgG), Immunoglobulin M (IgM)
2) By Application: Primary Immunodeficiency Disorders, Autoimmune Diseases, Neurological Disorders, Other Applications
3) By End-Use: Clinics, Hospitals, Homecare, Other End-Uses

North America was the largest region in the subcutaneous immunoglobulin market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the subcutaneous immunoglobulin (SCIG) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Intrigued to explore the contents? Secure your hands-on a free sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15935&type=smp

Major Driver Impacting Market Growth
The increase in the prevalence of secondary immunodeficiency diseases is expected to propel the growth of the subcutaneous immunoglobulin market going forward. Secondary immunodeficiency diseases are conditions with a reduced or compromised immune system caused by sources other than the immune system itself. The prevalence of secondary immunodeficiency diseases is driven by various factors such as aging populations, the use of immunosuppressive treatments, and environmental toxins. Subcutaneous immunoglobulin therapy provides antibodies to help strengthen the weakened immune system, especially in chronic disorders such as HIV or autoimmune diseases, thereby preventing infections and supporting immunological function during treatment. For instance, in October 2023, according to the UK Health Security Agency, a UK-based government agency, reported 3,805 new HIV diagnoses in England in 2022, representing a 22% rise from the previous year. Therefore, the increase in the prevalence of secondary immunodeficiency diseases is driving the growth of the subcutaneous immunoglobulin market.

Rising Neurological Disorders Fuel Growth In The Subcutaneous Immunoglobulin Market

The increasing number of neurological disorders is expected to propel the growth of the subcutaneous immunoglobulin market going forward. A neurological disorder is any disorder of the nervous system that includes anatomical, biochemical, or electrical abnormalities in the brain, spinal cord, or peripheral nerves such as acute spinal cord injury, alzheimer's dementia, amyotrophic lateral sclerosis (ALS), ataxia, brain tumors, and others. Neurological disorders are increasing due to various factors such as aging populations, environmental toxins, genetic predispositions, and lifestyle changes. Subcutaneous immunoglobulin therapy can be beneficial in neurological disorders by providing antibodies that modulate the immune response, reduce inflammation, and stabilize neuromuscular junctions, potentially slowing disease progression and improving symptoms. For instance, in March 2022, according to the Alzheimer's Association, a US-based nonprofit voluntary health organization reported that 6.5 million Americans aged 65 and older are currently living with Alzheimer's dementia, with projections indicating this number could reach 13.8 million by 2060. Therefore, the increasing number of neurological disorders is driving the growth of the subcutaneous immunoglobulin market.

Key Industry Players
Major companies operating in the subcutaneous immunoglobulin (SCIG) market are Pfizer Inc., Johnson & Johnson, Prothena Corporation plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Amgen Inc., Baxter International Inc., CSL Behring, Lonza Group, Grifols S.A., Octapharma AG, Dr. Reddy's Laboratories, Intas pharmaceutical Ltd., Emergent BioSolutions Inc., Kedrion Biopharma, LFB group, Biotest AG, Argenx SE, Bio Products Laboratory Ltd., ADMA Biologics Inc., Sino Biological Inc. , Bharat Serums and Vaccines Limited (BSV), Kamada Pharmaceuticals, CinnaGen Co., Shire plc

The subcutaneous immunoglobulin (scig) market report table of contents includes:

1. Executive Summary

2. Subcutaneous Immunoglobulin (SCIG) Market Characteristics

3. Subcutaneous Immunoglobulin (SCIG) Market Trends And Strategies

4. Subcutaneous Immunoglobulin (SCIG) Market - Macro Economic Scenario

5. Global Subcutaneous Immunoglobulin (SCIG) Market Size and Growth
............

32. Global Subcutaneous Immunoglobulin (SCIG) Market Competitive Benchmarking

33. Global Subcutaneous Immunoglobulin (SCIG) Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Subcutaneous Immunoglobulin (SCIG) Market

35. Subcutaneous Immunoglobulin (SCIG) Market Future Outlook and Potential Analysis

36. Appendix

Contact Us: